IgA Nephropathy clinical trials at UCSF

1 in progress, 0 open to eligible people

Atrasentan in Patients With IgA Nephropathy
Sorry, in progress, not accepting new patients
The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.
San Francisco, California and other locations

Last updated: May 26, 2023